Madrigal logo.jpg
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
May 29, 2024 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Tevogen Logo Notified.png
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024 08:00 ET | Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
Fractyl-Logo.png
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024 07:00 ET | Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Cellectis Logo.png
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET | Cellectis Inc.
•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 •  Conference...
image1 (1).png
Evaxion Announces Business Update and First Quarter 2024 Financial Results
May 28, 2024 08:21 ET | Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 28, 2024 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Logo Long.png
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
May 28, 2024 07:35 ET | Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:03 ET | Olema Oncology
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
NodThera_logo.jpg
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
May 28, 2024 07:00 ET | NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
54e32440-dc06-4e9b-8642-6d262b1eeb16.png
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress
May 28, 2024 02:00 ET | Mironid
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress LoAc® compound lowers renal cAMP after single or multiple doses and demonstrates efficacy in a...